Nadim Ahmed
Vermogen: 2 M $ op 30-06-2026
Vermogen: 2 M $ op 30-06-2026
Mr. Nadim Ahmed is a President, Chief Executive Officer & Director at Cullinan Therapeutics, Inc., a President, Chief Executive Officer & Director at Cullinan Mica Corp.
and a President, Chief Executive Officer & Director at Cullinan Pearl Corp.
He is on the Board of Directors at Disc Medicine, Inc., Cullinan Therapeutics, Inc., Family Promise, Cullinan Mica Corp.
and Cullinan Pearl Corp.
Mr. Ahmed was previously employed as a President, Chief Executive Officer & Director by Cullinan Oncology LLC, a President-Hematology by Bristol Myers Squibb Co., a President-Global Hematology & Oncology by Celgene Corp., and a Senior Marketing Director-Hematologic Oncology by GlaxoSmithKline LLC.
He received his undergraduate degree from the University College London and a graduate degree from Loughborough University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-04-2026 | 135.921 ( 0,23% ) | 2 M $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Algemeen Directeur | 18-10-2021 |
| DISC MEDICINE, INC. | Directeur/Bestuurslid | 14-07-2025 |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Directeur/Bestuurslid | - |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Algemeen Directeur | - |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Algemeen Directeur | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-01-2021 |
| CELGENE | Corporate Officer/Principal | 01-11-2019 |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 01-03-2010 |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Algemeen Directeur | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 11 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loughborough University
Loughborough University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Commercial Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Health Technology |
Cullinan Oncology, Inc.
Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau